Clinical Case Study: Post-Antibiotic Dysbiosis

Active Profile Case 3

Male Patient

Age: 36 • Post-Antibiotics: 3 Months

Core Symptoms: Loose stools, Cramping, Gas

Stool Character: Bristol 6, Urgent, Loose

Core History Gathered: 0 / 4 Core Explored

Teaching Target

Antibiotics can profoundly disrupt the gastrointestinal ecology, leading to low diversity and opportunistic expansions.

Intake Room Status: Awaiting Interview

Initial Clinical Presentation

A 36-year-old male presents with persistent post-prandial gas, cramping, and loose stools that began immediately after completing a course of broad-spectrum antibiotics three months ago.

“

"Ever since I finished that heavy course of antibiotics for my sinus infection three months ago, my digestion has been completely broken. My stool test is a sea of red flags—high bacteria, low good bugs, and yeast. I want to start a harsh herbal cleanse to kill off these bad bugs, but I'm terrified it will leave me even more depleted."

Step 1: Patient History

Cross-examine timing parameters, stool details, systemic concerns, and self-imposed dietary restrictions.

Step 2: Diagnostics

Unlock the pathobiont profile, yeast cultures, and essential mucosal immune data panels.

History Interview Core Explored: 0 of 4 Required

Patient Assessment Phase

Interview the patient to explore potential vulnerabilities, pharmaceutical triggers, and active coping behaviors. You must ask the 4 core clinical questions marked with a star (★) to proceed.

Q1: ★ Antibiotic class and course timing? ?

Q2: ★ Stool patterns, urgency, and consistency? ?

Q3: Dietary patterns before this illness? ?

Q4: ★ Dietary restrictions & carbohydrate avoidance? ?

Q5: ★ Alarm indicators, nocturnal stools, or blood? ?

Q6: Stress and sleep baselines? ?

Lab Data Panel Systemic Results Unlocked

Objective Laboratory Findings

Correlate ecological dysbiosis with systemic health. Be mindful of potential watery dilution artifacts on concentration metrics.

⚠️

Clinical Consistency Note: Patient stool sample is reported as Bristol Stool Type 6 (loose, unformed, watery). Watery stool can dilute fecal biomarkers, potentially lowering measured outputs artifactually.

Marker category	Measured level	Expected reference	Clinical reading
Clostridioides difficile Toxins A & B	Negative	Negative	C. diff Negative by Local Algorithm
Fecal Calprotectin	42 ug/g	< 50 ug/g	Normal (No active mucosal inflammatory migration)
Secretory IgA (sIgA)	380 ug/g	510 - 2010 ug/g	Low-normal; non-specific marker of altered mucosal tone
Klebsiella oxytoca	3+ (High)	< 1+ / None	Pathobiont Expansion
Morganella morganii	3+ (High)	< 1+ / None	Pathobiont Expansion
Candida albicans Culture	1+ (Low Growth)	None / Rare	Common commensal colonizer; not diagnostic of yeast overgrowth
Bifidobacterium spp.	Low-Detectable	Normal Range	Severe depletion of post-antibiotic keystone phyla
Faecalibacterium prausnitzii	Undetectable	Normal Range	Critical depletion of primary butyrate producer

Marker Name	Patient Value	Conventional Reference Range	Clinical Evaluation & Trend
CBC / Leukocytes	5.8 x10^3/uL	4.5 - 11.0 x10^3/uL	Normal; no active systemic leukocytosis
Comprehensive Metabolic (CMP)	Stable Baseline	Reference Normal	Glucose, electrolytes, kidney, and liver markers stable
High-Sensitivity CRP (hs-CRP)	0.8 mg/L	< 3.0 mg/L	Normal; absence of macro-inflammatory signaling
Erythrocyte Sedimentation Rate	5 mm/hr	< 15 mm/hr	Normal baseline vascular tone

Clinical Interpretation Step 4 of 6

Review Case Dynamics: A patient presents with persistent loose stools three months after broad-spectrum Augmentin. The stool report displays elevated opportunistic bacteria (Klebsiella, Morganella) and low-level yeast, alongside depleted beneficial anaerobes. Which clinical interpretation should be prioritized?

Active pathobiont infection requiring direct eradication

Deploy an aggressive herbal antimicrobial protocol targeting the 3+ Klebsiella and Morganella to clear the bowel infection.

Systemic yeast overgrowth (Candidiasis) driving localized leaks

Eradicate commensal Candida overgrowth with prescription antifungals to close mucosal barriers and restore stool consistency.

Post-antibiotic perturbation with loss of colonization resistance

Prioritize the profound depletion of native keystone anaerobes and loss of colonization resistance following pharmaceutical exposure.

Autoimmune mucosal immune collapse driven by low sIgA

Treat low fecal sIgA with high-dose bovine immunoglobulins and colostrum to stimulate mucosal defense tone first.

Confounder Evaluation Step 5 of 6

Understand Clinical Variables & Artifacts

Functional digestive testing requires careful methodological critique. Answer the following diagnostic context questions.

Part A: C. Difficile Surveillance

How should you clinically interpret the Negative C. difficile toxin EIA result?

1 A negative toxin EIA perfectly excludes all possibility of pathogenic colonizations, meaning no further surveillance is clinically justified.

2 Toxin EIA testing alone can miss cases. Diagnostic interpretation depends on clinical symptoms and local testing algorithms (such as GDH/PCR). Testing is highly relevant when diarrhea follows antibiotics.

Treatment Plan Triage Step 6 of 6

Determine the Correct Next Steps

How should you navigate post-antibiotic recovery parameters? Avoid therapeutic traps that treat the stool report like a "kill list."

Initiate an aggressive broad-spectrum antimicrobial cleanse (Oregano/Berberine)

Eradicate the expanded opportunistic pathobionts (Klebsiella and Morganella) immediately to "reset" the microbial baseline.

Avoid antimicrobial escalation, verify C. difficile algorithm, and implement phased substrate recovery

Refuse further non-selective clearance loops. Keep C. diff surveillance active, stop self-prescribed sweeps, and initiate a step-by-step soluble fiber/PHGG progression.

Impose a strict zero-carbohydrate elimination diet to starve out the yeast

Restrict all remaining fermentable carbohydrates to cut off fuel from commensal Candida, focusing the diet on proteins and fats only.

Clinical Debrief Case 3 Completed Successfully

Core Clinical Insight

"The stool test shows the aftermath of perturbation. The clinical task is to exclude true pathogens, avoid further nonselective disruption, and support recovery of function over time."

Interactive Treatment Outcome Predictor

Select a pathway below to project how the patient's ecosystem and symptoms will evolve based on your management choices.

📈

Microbial Reconstruction & Symptom Resolution By refusing further non-selective antimicrobials and gradually introducing soluble fibers (PHGG, psyllium, and cooked/cooled starches), you restore functional metabolic cross-feeding. Over 4-6 weeks, stool consistency transitions from Bristol 6 back to Bristol 4. The opportunistic pathobiont populations of Klebsiella and Morganella normalize naturally as obligate anaerobes regain competitive dominance.

Evidence-Based Phased Substrate Restoration

Phase 1 Soluble Fibers first

Phase 2 Gradual PHGG

Phase 3 Psyllium titration

Phase 4 Cooked/Cooled Starches

Phase 5 Polyphenol-rich foods

Phase 6 Highly fermentable prebiotics

Clinical Mastery Series